Omega Diagnostics Share Discussion Threads

[leedslad001] 01/12/2017 13:18

We can only hope. Have a good Christmas and a very prosperous 2018

[barrywhit] 01/12/2017 13:10

Hi Leeds, started talking last November, over a year ago, perhaps that's why the interims aren't until 14th December awaiting completion....

[leedslad001] 01/12/2017 12:49

Hi Barry agree this IDH tie up has gone on for far too long now needs signing off or walk away and use a different platform

[barrywhit] 01/12/2017 12:41

All we need now is the IDH contract tied up before the Interims......

[barrywhit] 01/12/2017 12:33

Well found rivaldo,

Another extract below:

“Burnet Institute is delighted to witness the commercial release of the VISITECT® CD4 test by our partners at Omega Diagnostics. Despite the adoption of broader HIV treatment access policies in many countries, the fact remains that many people are first diagnosed with advanced disease and low T cell counts that require additional interventions above and beyond just antiretroviral therapies.
“CD4 testing is critical for identifying the patients for whom these extra efforts are needed, and will remain an important tool in HIV treatment and care for many years.
“On behalf of our R&D team at Burnet, I would like to personally thank the Omega Diagnostics team for their persistence and dedication to our shared cause of bringing this vital test to reality – a perfect example of the right industry partnerships being able to help deliver Burnet’s vision of equity through better health.
“We expect that the VISITECT® CD4 test will make a real difference in HIV treatment and prevention programs that care for many millions of patients worldwide, which is exactly what we set out to achieve.”

[rivaldo] 01/12/2017 12:04

Nice PR from the Burnet Institute - very long piece about this "vital" new test:



Extracts:

"Vital HIV test now a reality

Tracy Parish
01 December, 2017

On World AIDS Day 2017, Omega Diagnostics, the medical diagnostics company focused on allergy, food intolerance and infectious disease, has announced with Burnet Institute the commercial release of its VISITECT® CD4 point-of-care test. The CE-Marking follows successful performance evaluations of the test in India and the UK....

....VISITECT® CD4, co-developed with the Burnet Institute, is the world’s first instrument-free and affordable rapid test for determining CD4 threshold in people living with HIV. It is designed for use at the point-of-care and provides a means for decentralisation of CD4 testing capacity to where it is most needed....

....“We expect that the VISITECT® CD4 test will make a real difference in HIV treatment and prevention programs that care for many millions of patients worldwide, which is exactly what we set out to achieve.”

[barrywhit] 01/12/2017 09:30

longshanks, nice to see you got a reply. My last email to the company wasn't replied to!!!

[longshanks] 01/12/2017 09:22

Last week I wrote to Andrew Shepherd suggesting it would be great if we could have Visitect CD4 CE marked in time for WAD.He has just replied."Trust you are well. For obvious reasons I could not answer your mail when it came in but you will now see that VISITECT CD4 is now CE Marked and the RNS has generated a lot of interest and press coverage as well as helping the share price pickup. We are working with our partners at Burnet on a wider release of the announcement to coincide with today's WAD events and next week we are attending/exhibiting at the ICASA Conference in Cote D'Ivoire where CD4 testing will be highly profiled.Many thanks for your support.Kind regardsAndrew"

[longshanks] 01/12/2017 08:41

The company certainly is very well positioned now for growth and would be an attractive bolt-on acquisition for a larger company.However, the shares are tightly held with ~65% owned by a very small group so I think it would require a decent mark-up on today's share price.Many of the directors options require 50p to vest, so were an offer to be tabled I would imagine it needs to be somewhere between 75p and £1 to assure success although on a long term view that would still be quite a steal.Anyway let's see where this goes now. If we can break 30p in the next month or two, it won't take much to lift it higher to 50p and beyond.

[barrywhit] 01/12/2017 08:40

Start of a rerate???

[barrywhit] 01/12/2017 08:31

Agree longshanks,

Overhang seems to have gone now back to normal trading.

Unfortunately at this market cap. we will be a tasty take out target for a few companies, hopefully with all the large holders the offer would have to be a good one....

[longshanks] 01/12/2017 08:24

Happy World AIDS Day everyone.Great to be a shareholder here in such a good news story for HIV sufferers in some of the poorest countries in the world.

[barrywhit] 30/11/2017 16:46

Nice to see the share price move upwards on small volume, perhaps the overhang has gone. Whoever is ramping will not have any joy as the Company is not one that will attract traders.....imo

[longshanks] 30/11/2017 16:09

I topped up with 7500.

Ummed and ahhed a bit and could have picked them up earlier today at 20.9p but that is the way it goes. News does appear to be percolating out.

Unfortunately it seems some can't help but ramp this stock on other bb sites. Nothing fundamentally wrong with making people aware but outright ramping is unacceptable. We have done a lot to keep the conversation level and the last thing I want is for the debate to start going the way of others through attracting frothy types.

Whoever is responsible - please desist.

[someuwin] 30/11/2017 15:41

Walbrook PR‏ @WalbrookPR · Nov 29

Omega Diagnostics Group plc (AIM: #ODX) has CE-Marked its VISITECT® CD4 test for helping to manage people living with HIV and are now available for sale in countries not requiring individual product registration

[cinquepercento] 30/11/2017 10:44

I often find that people put these shares on the back burner and don't check them every day with the result that the news takes a day or so to filter through.

[rivaldo] 30/11/2017 08:55

Good coverage in the Herald:



And the Times:



Extract:

"Yesterday, Omega confirmed that the CE Mark, a certification of quality, was in place after trials in India and Britain had shown that the kit was performing robustly. As a result it is available for sale to businesses in countries not requiring any additional product registration.

The company is now seeking approval through the World Health Organisation, which would allow the test to be made available through public sector procurement.

Finncap, the broker, estimates that annual revenue of up to £10 million could be achieved from the manufacturing capacity at Omega’s sites in Scotland and India."

[longshanks] 29/11/2017 15:59

This is a great milestone but I guess the muted response is because it is relatively earnings neutral in the short term. Often with such news events though it can take some days for it to reach those making long term investment decisions. In that regard, it could be that today's small rise is the start of a re-rate towards 30p.

[barrywhit] 29/11/2017 15:44

I am amazed at the trading today, the news we have been waiting for and the share price has done nothing now less than a 8% increase....all the smallish sells are puzzling...

[barrywhit] 29/11/2017 12:18

A couple of delayed buys just showing 100k & 150k,,,,,must be quite an overhang of stock available......

[rivaldo] 29/11/2017 11:23

Finncap retain their 30p target price - here's a couple of extracts:

"Visitect CD4 test CE-marked

In line with management’s long-established guidance for Q4 2017, the
company has achieved the significant regulatory milestone of CE-Marking
VISTECT CD4, following the successful completion of performance
evaluation studies in India and the UK. Initially, this will enable the limited
sale of Visitect CD4 on a B2B basis. The next step is to enter the WHO
Prequalification process (c.12 months) which is required to enable ODX to
sell into the larger NGO and UN procurement programmes, a market
estimated as many millions of tests. No change to forecasts or current
target price."

"Financial. ODX has the capacity to produce c.2.5m tests pa. on a single shift
basis.. Assuming market demand at this level, a list price of c.$5 (£4) per test
this could generate revenues of c.£10m.

 Valuation. We retain our target price of 30p which implies a calendar-adjusted
2018 EV/Sales multiple of 2.0x, which is in line with a peer group of diagnostic
companies. We are not changing our forecasts as B2B quantum is difficult to
gauge and likely to be opportunistic. As WHO PQ process becomes clearer we
should be able to build sales into our FY 2019/2020 forecasts and valuation."

[barrywhit] 29/11/2017 11:16

who the hell is selling these piddling little amounts......LOL

[longshanks] 29/11/2017 10:25

We know there has been a seller and it looks like there is still a big block of shares to clear. I would imagine it won't take much more though.I may well buy a few more myself.

[whites123] 29/11/2017 10:22

Unbelievable the muted interest in todays ground breaking news.
OK, it was expected and anticipated, but 2 days ahead of World Aids Day and 2 weeks ahead of results...

Come On......

Should be trading nearer 50p than the 20p mark...

[barrywhit] 29/11/2017 10:15

would of expected more than an 8% increase in share price ....